Logo

BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

Share this

BMS’ Abecma (idecabtagene vicleucel) Receives MHLW Approval for the Treatment of Multiple Myeloma

Shots:

  • The approval is based on the P-II (BB2121-MM-001) study & the P-I (CRB-401) dose-expansion & escalation cohort to evaluate Abecma in 149 & 67 patients with r/r MM who have received 3 prior therapies including an immunomodulatory agent, a proteasome inhibitor & anti-CD38 Ab
  • In the P-II trial, the therapy showed ORR (73.4%) in 128 non-Japanese patients at a target dose of 150, 300, or 450 x 106 & ORR (88.9%) in 9 Japanese patients at the target dose of 450 x 106. In the P-I trial, ORR (74.2%) in the 62 patients & 84.2% in the 38 patients (target dose of 450 x 106)
  • Abecma is a BCMA-directed CAR T cell immunotherapy & 1st CAR T cell therapy approved for r/r MM in Japan

Ref: BMS | Image: BMS

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions